JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

NCT06416410 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

392

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer
Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions

DRUG: JAB-21822
DRUG: Tislelizumab
DRUG: JAB-3312
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Allist Pharmaceuticals, Inc.